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Summary Nebulisation chemotherapy, a chemotherapeutic method for the treatment of lung cancer that
involves the administration of anticancer agents through the inhalation of nebulised aerosols, has been found
to be highly effective (Tatsumura et al., 1983a,b). We confirmed that 5-FU administered by this method
accumulates in the trachea, bronchi and regional lymph nodes of patients treated before surgery, along with
5-FU metabolites, FUR and FUdR, indicating that 5-FU is directly incorporated and metabolised in the
respiratory tract. Parallel result were obtained using mongrel dogs. The 5-FU levels in other organs, such as
the heart and liver, were found to be extremely low. Only a trace of 5-FU was found in the serum of both the
patients and the dogs. We further investigated the anti-tumour effect of this therapy in ten selected patients
and observed a satisfactory anti-tumour response of 60.0%. These results, along with our previous finding that
the retention time ofisotope tracers inhaled as aerosol is considerably longer in tumour tissues than in normal
parts (Tatsumura et al., 1983a) explain the high antitumour action of this therapy and the absence of adverse
effects of administered 5-FU.
In cancer chemotherapy, the ideal treatment involves the
administration of high concentrations of anticancer agents
directly and continuously to the target tumour tissue, allow-
ing the agents to exert their maximum cytocidal effects on the
tumour without adversely affecting the other organs. A new
chemotherapeutic method called 'nebulisation chemotherapy'
(NC therapy) was developed for this purpose. This therapy
involves the inhalation of ultrasonically nebulised aerosol
particles of anticancer agent through the oral cavity and
bronchial tree. The technique allows direct and prolonged
action of high concentration 5-FU on the tumour tissue of
lung cancer. Previous studies have reported strong responses
by patients to this form of therapy (Tatsumura et al.,
1983a,b). The present study further supports the therapeutic
value of this method and presents some data which help
explain how this therapy works.
Materials and methods
Administration andanalysis of5-FU in mongrel dogs
The concentrations of 5-FU and its metabolites, FUR and
FUdR, in the tissues and sera were measured using a recently
developed, high-performance liquid chromatographic
(HPLC) method (Masuike et al., 1985).
Eighteen mongrel dogs weighing 15.5-16.5 kg were used in
the experiment. All dogs were anaesthetised with ketamine
hydrochloride (Ketalar) (10-20 mgkg-') and atropine sulfate
(0.03-0.04 mg kg-'). They were then intubated, mechanically
ventilated, and given supplementary oxygen. Anaesthesia was
maintained by an intravenous administration of pentobar-
bital (5-10 mg kg-'). The inhalant was prepared by mixing
5-FU (50 mgkg-') with expectorant, was nebulised by an
ultrasonic nebuliser, and was then sent into the respiratory
apparatus. Oxygen was supplied to the circuit at a rate of
21/min and ventilation was carried out at 100-150 mlmin-'
at 20 times/min. This circuit carried the aerosol to the bron-
chial trees at the alveolar level.
Cardiac arrest was induced by an intravenous injection of
KCI after each procedure. Tissue samples were collected after
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1 h (Group 1), 2 h (Group 2) and 4 h (Group 3) of exposure
to the nebulised 5-FU and were stored at - 40°C until used
for measurement. Each experimental group contained six
dogs. Tissue samples were removed from the wall of the
trachea, the bifurcation of trachea, the bilateral main bron-
chi, and the peripheral pulmonary parenchyma. Regional
lymph nodes, including those of the paratracheal, carinal
region, and the nodes around both main bronchi were extir-
pated along with the other tissues. Other tissues, such as the
liver, pancreas, kidneys, esophagus, stomach, small and large
intestines, spleen, and myocardium were also taken as speci-
mens in order to evaluate the adverse effects of this therapy.
Serial serum samples were obtained through an arterial
line connected to the femoral artery in dogs. Samples were
collected at 5, 10 and 15 min during the treatment, and at 5,
15 and 30min after the treatment, and every 30min there-
after, before the animals were sacrificed. Separated serum
samples were stored at -40°C until needed for quantitation.
5-FU analysis in lung cancerpatients treated by NC therapy
In this study, 19 patients with lung cancer underwent nebu-
lisation therapy with 5-FU (250 mg/5 ml; 2.5 mgkg-')
approximately 2 h before surgery. Normal lung tissue sam-
ples were obtained during surgery from the pulmonary lobe
that was to be extirpated, and from the lymph nodes of the
hilar and mediastinal regions during dissection. Tumour tis-
sue was collected simultaneously as the affected lobe was
resected. Serial serum samples were also collected simul-
taneously at the time of tissue collection from each patient.
Tissue and serum samples were immediately stored at
-40°C. Quantitation was performed by HPLC.
Clinicalstudy oflung cancerpatients
Ten patients were selected for this therapy to further evaluate
the anti-tumour effects of nebulisation chemotherapy. None
of the patients had been subjected to any chemotherapy or
radiotherapy prior to this therapy. Those selected for the
present investigation were patients diagnosed as inoperable,
whether due to the advanced condition of their disease,
which showed distal metastasis, or due to old age and poor
cardiopulmonary function.
Five of the ten cases had primary main bronchial carci-
noma, showing invasion to the carina and/or into the contra-
lateral side main bronchi. All of these cases involved
squamous cell carcinomas, including two cases with metas-
tatic lymph nodes of primary lung cancer, showing direct
invasion of the metastatic nodes to the carina. One case was
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squamous cell carcinoma and the other case was adenocar-
cinoma. Two of the others were primary squamous cell car-
cinomas of the right and left upper lobes that showed
invasion to the main bronchi. The remaining case was a
recurrence of a bilateral metastatic lung cancer resulting from
postoperative adenocarcinoma of lung cancer. Metastatic
lesions were noted in the remaining portions of the left lower
lobe, and the upper and lower portions of the right lobe. In
this series, there were nine males and one female, ranging
from 54 to 76 years of age, with a mean of 67.0 years.
The patients were given a mixture of 5-FU and Bisolvon
(1-2 ml), vaporised by a supersonic nebuliser. The 5-FU
used in this treatment was the same solution generally pre-
pared for intravenous injection (250mg/5 ml per vial). The
aerosol was inhaled through the mouth into the trancheo-
bronchial trees for 10-15 min per treatment. Inpatients
received this therapy twice a day on 2 to 3 days per week.
The one outpatient in this series was treated once per visit,
which was once per week. A standard dose of 250 mg of
5-FU per day was applied. Before each treatment, the patient
was required to gargle with milk to prevent stomatitis that
might be induced by 5-FU. After each therapy, the oral
cavity was rinsed thoroughly with tap water to remove excess
5-FU in the buccal membrane. The treatment was given in a
room equipped with a ventilating device to clear away excess
5-FU aerosols. The output of the aerosols is adjusted
through the nebuliser apparatus to an adequate volume to
inhale, so to minimise the leakage of the 5-FU aerosols
during the therapy.
Results
Table I summarises the results of the 5-FU series performed
on the dogs. High concentrations of 5-FU were detected in
the tracheal wall and the bronchial wall of the hilar region in
the dogs treated by NC therapy. The 5-FU concentration in
the trachea decreased with time. However, the concentration
in the hilar bronchi showed an increase that was maintained
even after 4 h post-treatment. In contrast, the concentration
of 5-FU in the peripheral lung tissue was only roughly
one-tenth of the levels in the trachea and bronchi of the hilar
region.
The highest levels of 5-FU in the lymph nodes were detect-
ed in the peribronchial regions of the right and left main
Table I Levelsof5-FU invariousorgansofmongrelsafterNCtherapy
(5-FU 50 mg kg-')
I h 2h 4h
Organs mean±s.d. mean±s.d. mean±s.d.
Trachea 5.84±4.5 2.42± 3.12 0.18±0.20
Hilar bronchus 0.29±0.22 1.10± 1.29 1.06±0.98
Lymph node at main
bronchial level 0.133±0.04 0.19± 0.08 0.12±0.06
Peripheral lung 0.04±0.01 0.12±0.11 0.047±0.02
Esophagus 0.33±0.42 0.38±0.23 0.21±0.21





Liver 0.041 ±0.01 0.049±0.028 0.038±0.024
Kidney 0.036±0.015
bronchi in the hilar regions. The levels were 0.13 ± 0.04 jig
g-I at I h, 0.19 ± 0.08 igg-I at 2 h, and 0.12 ± 0.06,gg-I
at 4 h. The corresponding levels in the lymph nodes of
bifurcation were 0.05 ± 0.01 jig g-' (1 h), 0.08 ± 0.04 jig g-'
(2 h), and 0.12 ± 0.05 ,ug g-' (4 h). The corresponding levels
in the peritracheal nodes were 0.09 ± 0.03 jig g-', 0.06 0.03
jg g ' and 0.03 ± 0.02 jig g-', respectively.
The serum concentration of 5-FU in dogs was 0.27 0.11
jig ml- ' after 5min, 0.30 ± 0.09 jig ml-', after 10 min, and
0.23 ± 0.13 jig ml-', at the end of the 15 min treatment. The
concentrations of 5-FU gradually decreased to below the
limit of quantitation, between 30min (0.02 ± 0.02 jigml-')
and 45 min (0.01 ± 0.02 jig ml-') after the end of treatment.
Relatively high levels of 5-FU were found in the esophagus
(presumably due to swallowing during therapy) the stomach,
and the liver. In the myocardium, the highest concentration
was only 0.02 ± 0.02 ig g-'. However, in the pancreas and
spleen, the 5-FU levels were below the quantitation limit.
Table II summarises the analytical results obtained from
the series performed on mongrel dogs. The highest concen-
trations of FUR were found in the trachea and bronchi of
the hilar region. Concentrations in the peripheral lung tissues
were under the quantitation limit. We found FUdR only in
the trachea and bronchi of the dogs sacrificed 4 h after
treatment.
Table III shows that significantly higher levels of 5-FU
were observed in the tumour tissue (per gram of tumour
tissue) compared to the normal lung tissue (per gram of
normal lung tissue) (f-test, P<0.05). The concentrations of
5-FU were 5-15 times higher in tissues sampled from lung
cancer of the hilar type, than in tissues obtained from the
marginal area of tumours (per gram of normal lung tissue).
The concentrations of 5-FU in the regional lymph nodes
were also marked, showing higher levels in the hilar region
than in the mediastinal nodes (Table III). 5-FU was not
detected in any of the blood samples that were obtained
during surgery, at the time the related tissues were removed.
Six of the ten patients who were subjected to this therapy,
showed some response, with two showing a complete res-
ponse (CR) (Figure 1), and four showing a partial response
(PR). The remaining four cases showed no detectable im-
provement during the treatment period. Three of these
patients died of their disease due to dissemination, and
therapy had to stop in last case due to a general deterioration
of the patient's condition from dissemination of the disease.
Only 1750 mg of 5-FU had been administered by the time the
treatment was stopped. The CR cases were administered a
mean of 11,750 mg 5-FU (range 10,500-13,000 mg) and the
PR group was administered a mean of 5875 mg (range
4750-7520 mg) (Table IV). In the non-response group the
mean was only 2500 mg 5-FU (range 1750-3250 mg). No
stomatitis or any other notable side-effects were observed in
this series too.
Discussion
This therapy depends upon the transportation of fine par-
ticles of ultrasonically nebulised 5-FU through the mouth to
the tumour tissue. Previous studies have shown that more
than 50% of particles with a 1-5 jLm diameter can reach the
peripheral bronchi to the alveolar level (Task Group on
Lung Dynamics, 1966; Wolfsdorf, 1969). Other studies have
Table 11 Concentrations ofFUR and FUdR in various tissues ofthe respiratory tract in mongrels treated
with NC therapy (5-FU 50 mg kg-')
FUR FUdR
Organs I h 2h 4h lh 2h 4h
mean±s.d. mean±s.d. mean±s.d. mean±s.d. mean±s.d. mean±s.d.
Tracheal wall 1.54± 1.03 0.90±0.34 0.10±0.08 0 0 0.12±0.12
Bronchial wall
(at hilal) 0.28±0.18 1.14± 1.60 0.67±0.50 0 0 0.18±0.15
Peripheral lung 0 0 0 0 0 01148 T. TATSUMURA et al.
TableIII Levelsof5-FU inthetissuesofthenormallungand nodesin




Normal lung tissue 0.00-0.06 0.03 ±0.018 (n = 13)
Tumour tissue 0.02-0.31 0.086±0.072 (n = 13)
Hilar node 0.01-0.08 0.042±0.23 (n = 13)
Mediastinal node 0.00-0.05 0.027±0.015 (n = 8)
Table IV Chemotherapeutic results of NC therapy in present series
Therapeutic Response rate Mean total of
response No. ofcases (%) S-FU (mg)
CR 2 20% 11,750
PR 4 40% 5,875
NC 4 40% 2,500
CR: complete disappearance of the tumour; PR: a reduction of
greaterthan50% inthesizeofthegreatestperpendiculardiameterofthe
tumour; NC: no significant change in the size of the tumour.
shown that this therapy, when clinically applied, can be
remarkably efficient, presumably because of the high local
concentration and prolonged, constant action by 5-FU on
the tumour tissue (Tatsumara et al., 1983a,b).
The results obtained in this study regarding the distribu-
tion of 5-FU in the organs of dogs revealed not only high
concentrations of 5-FU in the walls of the trachea and
bronchi but also the presence of the metabolites of 5-FU,
FUR, and FUdR in the tissues. This clearly indicates that
5-FU is directly incorporated and metabolised in bronchial
epithelial cells. It is reasonable to expect that 5-FU is also
absorbed by the cells of tracheal and bronchial carcinomas in
a similar manner and that this route of administration is
more efficient than existing methods. In fact, the 5-FU con-
centrations found in the tumour tissue were 5-15 times
higher than those in the surrounding normal tissue, a level
that has not been attained by conventional intravenous or
per os methods of administration.
The antitumour effects of 5-FU have been shown to take
place at a level of 0.05 mg g' tissue (Eguchi et al., 1979).
The mean 5-FU level found in this study after 4-6 h in the
tumour tissue ofpatients treated preoperatively was 0.086 mg
g' tissue, which exceeds this effective level and is in accor-
dance with the high efficacy observed.
Using isotopes in the inhalation scanning method, we have
previously shown that the ciliary movement of bronchial
trees is disturbed by the presence of tumours exposed on the
lumen of the respiratory tract, which can retard the excretion
function (Tatsumura et al., 1983a). This physiological pheno-
menon is an important factor in the present method of
therapy because it allows the prolonged contact of high-
concentration anticancer agents within the tumour tissue.
Furthermore, the destruction of bronchial cilia by the
tumour would allow 5-FU to accumulate at the site for a
longer period, resulting in a higher intake by the tumour
cells.
It is known that 5-FU is a carcinostatic agent and that its
action is dependent or cell cycle and time (Skipper et al.,
1970), and, further, that its incorporation into the cell is
increased if the cell has been grown in a medium that is rich
in 5-FU. When normal ciliary movement has been disrupted,
5-FU can become localised and sustains its contact on the
cancerous tissue which may be another factor explaining the
efficacy of the present method.
The present results show that, following treatment, there
are relatively high levels of 5-FU in regional lymph nodes, in
both human patients and in dogs. This suggests that 5-FU
was absorbed in the bronchial tree and into the lymphatic
path. Therefore, the present method also might be useful in
the clinical treatment of metastatic lymph nodes in cases of
lung cancer.
b
Figure 1 a, Easy-bleeding squamous cell carcinoma overriding
the carina to the contralateral main bronchus, predominantly of
the right main bronchus of a 70-year-old male. b, Marked regres-
sion of the tumour was noted after NC therapy with a total dose
of 5-FU 3,200 mg. c, After a total dose of 5-FU 10,000 mg
inhaled, complete regression of the tumour was observed.
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However, in order to insure that high concentrations of the
5-FU aerosols reach the tumour tissue during therapy,
inhalation of the aerosols should be properly performed with
periodic and repeated deep inspiration. If inhalation is not
properly performed, then the 5-FU aerosols will be confined
to the oral cavity or to the laryngopharyngeal region, and the
desired anti-tumour effect will not be obtained.
Previous studies have shown that 5-FU increases the radio-
sensitivity of tumour cells, when applied concomittantly with
radiotherapy (Bruce, 1967; Collin et al., 1962; Bagshaw,
1963; Lowry, 1965; Hodnett, 1970). The combination of
these two therapies would be highly effective and may allow
a reduction in the radiation dose that is normally applied.
The potential side effects of this therapy to the bronchial
tree were evaluated with a routine bronchoscopic study dur-
ing the therapy, in all of the clinical cases. To date, no
occurrence of bronchitis, ulceration of the normal bronchial
trees, or pneumonitis has been detected. Furthermore, there
has been no hazardous complication of the respiratory tract
in those patients treated in our department or in the related
hospital, as preoperative therapy or as adjuvant therapy for
inoperable cases. It appears that 5-FU inhalation is well
tolerated by the bronchial tree and normal lung tissue.
No systemic hazardous effects related to this therapy have
been clinically observed. This is verified by the extremely low
level of 5-FU in blood after the therapy (Tatsumara et al.,
1983a). Several cases of stomatitis were experienced in the
early phase of treatment but this complication was entirely
eliminated by instructing the patient to moisten the oral
cavity with milk and by gargling after the treatment.
From a clinical standpoint, this therapy provides various
advantages beyond the absence of side effects. It requires
only a simple and inexpensive ultrasonic nebuliser apparatus
and requires only 15 min for single administration, resulting
in significant saving in both expenses and time.
Conclusion
The results of analysis on tissues and sera of experimental
dogs and preoperative cancer patients for 5-FU and meta-
bolites administered by NC therapy revealed especially high
concentrations of 5-FU in tumour tissue and in lymph nodes.
The anti-tumour effects of this therapy have also been re-
confirmed by the present cases. These observations supported
and explained the high efficacy of this therapy for lung
cancer, as previously reported and appear to justify the wider
use of this method.
This study was supported by a Grant-in-aid for scientific research
from the Japanese Ministry of Education, No. 59480291.
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